DTIL

7.4007.09%
GJ

Geno J. Germano

Independent Chairman

Mr. Geno J. Germano serves as Independent Director since October 19, 2026 at Eloxx Pharmaceuticals, Inc. He is Pharmaceutical & Legal Advisory Board Member of Adjuvia Therapeutics, Inc. Mr. Germano is Independent Director of Harmony Biosciences Holdings, Inc. from May 14, 2026. Mr. Germano is an Independent Chairman of Entera Bio Ltd. since February 4, 2026. He was Director of Orbital Therapeutics Inc. from March 2025 to December 2025. Mr. Germano has been an Independent Director of Precision BioSciences, Inc. since March 10, 2020. Mr. Germano served as the President, Chief Executive Officer and Director of Elucida Oncology, Inc. since August 2018. Mr. Germano served as the President at Intrexon Corporation from June 01, 2016 to March 10, 2017. Mr. Germano has extensive experience in the pharmaceutical industry and a consistent track record of improving operating performance and increasing shareholder value across a broad range of leadership roles in therapeutic categories and global markets at Pfizer, Wyeth and Johnson & Johnson. Mr. Germano was a global biopharmaceutical industry executive with more than three decades of experience. He served as Group President of Global Innovative Pharma Business at Pfizer Inc. from January 1, 2014 to February 8, 2016, where he led a growing global business with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas, including cardiovascular, metabolic disease, neuroscience, inflammation, immunology and rare diseases. He served as the President of Specialty Care & Oncology and General Manager of Specialty Care and Oncology of Pfizer Inc. from December 2010 to December 2013 and also served as its Head of Specialty Businesses from October 2009 to December 2010. He served as the President of U S Division and General Manager of Wyeth Pharmaceuticals, Inc. since January 2008 and February 22, 2007 respectively. He was responsible for delivery of operational results across four business units, as well as President of Global Pharmaceutical and Women's Healthcare Business at Wyeth Pharmaceuticals, Inc. since January 2008. He joined Pfizer in October 2009 and has held various positions, including President and General Manager, Specialty Care. He joined Wyeth in 1984 as a Sales Representative and has held positions of increasing responsibility in Sales, Marketing, Business Development and General Management, including Managing Director, Wyeth Australia and New Zealand and Executive Vice President and General Manager for Global Vaccines of Wyeth Pharmaceuticals from 2002 to 2004. He served as Executive Vice President, Pharmaceutical Business Unit of Wyeth Pharmaceuticals from 2004 to 2007. He served as an Independent Director of The Medicines Company from November 15, 2017 to January 6, 2020. He served as a Director of Bioverativ Inc. from May 15, 2017 to March 8, 2018. He was an Independent Director of Sage Therapeutics, Inc. since July 19, 2016 until July 31, 2025 and was its Chair of the Board since January 05, 2024 until July 31, 2025. Mr. Germano joined the Sage Therapeutics, Inc. on July 19, 2016. He served as a Director of Zoetis Inc. from July 2012 to June 2013. He is a Member of Group of Fifty (G50) and serves on the Board of the Biotechnology Innovation Organization, as well as on the Advisory Board of the Healthcare Businesswomen's Association and as a Trustee of the Albany College of Pharmacy and Health Sciences. Mr. Germano received his B.S. in Pharmacy from Albany College of Pharmacy.

Positions